Noncollagenous bone matrix proteins, calcification, and thrombosis in carotid artery atherosclerosis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 8, 1999, Pages 1852-1861

  Bini, Alessandra ^a   Mann, Kenneth G ^b   Kudryk, Bohdan J ^a   Schoen, Frederick J ^c  

^a NEW YORK BLOOD CENTER   (United States)

^b UNIVERSITY OF VERMONT   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Atherosclerosis; Bone matrix proteins; Calcification; Fibrin(ogen); Matrix metalloproteinases

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E; CALCIUM PHOSPHATE; CHOLESTEROL; D DIMER; FIBRIN; FIBRINOGEN; GELATINASE A; LIPOPROTEIN A; OSTEOCALCIN; OSTEONECTIN; OSTEOPONTIN; STROMELYSIN;

ARTERY CALCIFICATION; ARTICLE; ATHEROSCLEROSIS; CAROTID ENDARTERECTOMY; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MACROPHAGE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; THROMBOSIS; VASCULAR ENDOTHELIUM;

EID: 0032776760     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.8.1852     Document Type: Article

References (74)

1. Beadenkopf WG, Daoud AS, Love BM. Calcification in the coronary arteries and its relationship to arteriosclerosis and myocardial infarction. AJR Am J Roentgenol. 1964;92:865-871.
2. Honye J, Maon DJ, Jain A, White CJ, Ramee SR, Wallis JB, Al-Zarka A, Tobis JM. Morphological effects of coronary balloon angioplasty in vivo assessed by intravascular ultrasound imaging. Circulation. 1992;85: 1012-1025.
3. Hirsch D, Azoury R, Sarig S, Kruth HS. Colocalization of cholesterol and hydroxyapatite in human atherosclerotic lesions. Calcif Tissue Int. 1993; 52:94-98.
4. Sangiorgi G, Rumberger JA, Severson A, Edwards WD, Gregoire J, Fitzpatrick LA, Schwartz RS. Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying methodology. J Am Coll Cardiol. 1998;31:126-133.
5. Mintz GS, Pichard AD, Popma JJ, Kent KM, Satler LF, Bucher TA, Leon MB. Determinants and correlates of target lesion calcium in coronary artery disease: a clinical, angiographic and intravascular ultrasound study. J Am Coll Cardiol. 1997;29:268-274.
6. Hirota S, Imakita M, Kohri K, Ito A, Morii E, Adachi S, Kim H-M, Kitamura Y, Yutani C, Nomura S. Expression of osteopontin messenger RNA by macrophages in atherosclerotic plaques: a possible association with calcification,. Am J Pathol. 1993;143:1003-1008.
7. Stenner DD, Tracy RP, Riggs BL, Mann KG. Human platelets contain and secrete osteonectin, a major protein of mineralized bone. Proc Natl Acad Sci U S A. 1986;83:6892-6896.
8. Young MF, Day AD, Dominquez P, McQuillan CI, Fisher LW, Termine JD. Structure and expression of osteonectin mRNA in human tissue. Connect Tissue Res. 1990;24:17-28.
9. +2-dependent binding to the extracellular matrix. J Cell Biol. 1989;109:341-356.
10. Mason IJ, Taylor AT, Williams JG, Sage H, Hogan BLM. Evidence from molecular cloning that SPARC, a major product of mouse embryo parietal endoderm, is related to an endothelial cell "culture shock" glycoprotein of Mr 43 000. EMBO J. 1986;5:1465-1472.
11. Wewer UM, Albrechtsen R, Fisher LW, Young MF, Termine JD. Osteonectin/SPARC/BM-40 in human decidua and carcinoma, tissue characterized by de novo formation of basement membrane. Am J Pathol. 1988;132:345-355.
12. Engel J, Taylor W, Paulsson M, Sage H, Hogan B. Calcium binding domains and calcium-induced conformational transition of SPARC/BM-40/osteonectin, an extracellular glycoprotein expressed in mineralized and nonmineralized tissues. Biochemistry. 1987;26:6958-6965.
13. Kelm RJJ, Swords NA, Orfeo T, Mann KG. Osteonectin in matrix remodeling: a plasminogen-osteonectin-collagen complex. J Biol Chem. 1994;48:30147-30152.
14. Hasselaar P, Loskutoff DJ, Sawdey M, Sage EH. SPARC induces the expression of type 1 plasminogen activator inhibitor in cultured bovine aortic endothelial cells. J Biol Chem. 1991;266:13178-13184.
15. Tremble PM, Lane TF, Sage EH, Werb Z. SPARC, a secreted protein associated with morphogenesis and tissue remodeling, induces expression of metalloproteinases in fibroblasts through a novel extracellular matrix-dependent pathway. J Cell Biol. 1993;121:1433-1444.
16. Henney AM, Wakeley PR, Davies MJ, Foster K, Hembry R, Murphy G, Humphries S. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci U S A. 1991;88:8154-8158.
17. Galis ZS, Sukhova GK, Lark MW, .Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94: 2493-2503.
18. Li Z, Li L, Zielke R, Cheng L, Xiao R, Crow MT, Stetler-Stevenson WG. Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. Am J Pathol. 1996;148:121-128.
19. Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions: association of active enzyme synthesis with unstable angina. Circulation. 1995;91: 2125-2131.
20. Bini A, Itoh Y, Kudryk BJ, Nagase H. Degradation of cross-linked fibrin by matrix metalloproteinase 3 (stromelysin 1): hydrolysis of the γ-Gly 404-Ala 405 peptide bond. Biochemistry. 1996;35:13056-13063.
21. Bini A, Kudryk BJ, Schnuer J. Characterization of fragments D-dimer and D-like monomer obtained by degradation of cross-linked fibrin with matrix metalloproteinase (MMP)-7 (matrilysin) and MMP-3 (stromelysin 1). Blood. 1997;90:465a. Abstract.
22. O'Brien ER, Garvin MG, Stewart DK, Hinohara T, Simpson JB, Schwartz SS, Giachelli CM. Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler Thromb. 1994;14: 1648-1656.
23. Shanahan CM, Cary NRB, Metcalfe JC, Weissberg PL. High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest. 1994;93:2393-2402.
24. Ikeda T, Shirasawa T, Esaki S, Yoshiki S, Hirokawa K. Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta. Am J Pathol. 1993;143:1003-1008.
25. Fitzpatrick LA, Severson A, Edwards WD, Ingram RT. Diffuse calcification in human coronary arteries: association of osteopontin with atherosclerosis. J Clin Invest. 1994;94:1597-1604.
26. Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz SM. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest. 1993;92:1686-1696.
27. Thiede MA, Smock SL, Peterson DN, Grasser WA, Thompson SK, Nishimoto SK. Presence of messenger ribonucleic acid encoding osteocalcin, a marker of bone turnover, in bone marrow megakaryocytes and peripheral blood platelets. Endocrinology. 1994;135:929-937.
28. Aeschlimann D, Mosher D, Paulsson M. Tissue transglutaminase and factor XIII in cartilage and bone remodeling. Semin Thromb Hemost. 1996;22:437-443.
29. Chenu C, Delmas PD. Platelets contribute to circulating levels of bone sialoprotein in human. J Bone Miner Res. 1992;7:47-54.
30. Chenu C, Colucci S, Grano M, Zigrino P, Barattolo R, Zambonin G, Baldini N, Vergnaud P, Delmas PD, Zalone AZ. Osteocalcin induces chemotaxis, secretion of matrix proteins, and calcium-mediated intra-cellular signaling in human osteoclast-like cells. J Cell Biol. 1994;127: 1149-1158.
31. Gijsbers BLMG, Van Haarlem LJM, Soute BAM, Ebberink RHM, Vermeer C. Characterization of a Gla-containing protein from calcified human atherosclerotic plaques. Arteriosclerosis. 1990;10:991-995.
32. Levy RJ, Lian JB, Gallop P. Atherocalcin, a γ-carboxyglutamic acid containing protein from atherosclerotic plaque. Biochem Biophys Res Commun. 1979;91:41-49.
33. Watson KE, Boström K, Ravindranath R, Lam T, Norton B, Demer LL. TGF-β1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify. J Clin Invest. 1994;93:2106-2113.
34. Bini A, Fenoglio JJ Jr, Mesa-Tejada R, Kudryk B, Kaplan KL. Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis. Arteriosclerosis. 1989;9:109-121.
35. Lee RT, Richardson SG, Loree HM, Grodzinsky AJ, Gharib SA, Schoen FJ, Pandian N. Prediction of mechanical properties of human atherosclerotic tissue by high-frequency intravascular ultrasound imaging: an in vitro study. Arterioscler Thromb. 1992;12:1-5.
36. Luna LG. Manual of Histologic Staining Methods of the Armed Forces Institute of Pathology. 1968.
37. Frank JD, Balena R, Masarachia P, Seedor JG, Cartwright ME. The effects of three different demineralization agents on osteopontin localization in adult rat bone using immunohistochemistry. Histochemistry. 1993;99:295-301.
38. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull WJ, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Atherosclerosis, American Heart Association. Circulation. 1995;92:1355-1374.
39. Bini A, Mesa-Tejada R, Fenoglio JJ Jr, Kudryk B, Kaplan KL. Immunohistochemical characterization of fibrin(ogen)-related antigens in human tissues using monoclonal antibodies. Lab Invest. 1989;60: 814-821.
40. Stenner DD, Romberg RW, Tracy RP, Katzmann JA, Riggs BL, Mann KG. Monoclonal antibodies to native non collagenous bone-specific proteins. Proc Natl Acad Sci U S A. 1984;81:2868-2872.
41. Gorski JP, Griffin D, Dudley G, Stanford C, Thomas R, Huang C, Lai E, Karr B, Solursh M. Bone acidic glycoprotein-75 is a major synthetic product of osteoblastic cells and localized as 75- and/or 50-kDa forms in mineralized phase of bone and growth plate and in serum. J Biol Chem. 1990;265:14956-14963.
42. Young MF, Kerr JM, Termine JD, Wever UM, Wang MG, McBride OW, Fisher LW. cDNA cloning, mRNA distribution and heterogeneity, chromosomal localization and RFLP analysis of human osteopontin (OPN). Genomics. 1990;7:491-502.
43. Fisher LW, Stubbs JTI, Young MF. Antisera and cDNA probes to human and certain animal model bone matrix noncollagenous proteins. Acta Orthop Scand. 1995;66:61-65.
44. Moskowitz KA, Kudryk B, Coller BS. Fibrinogen coating density affects the conformation of immobilized fibrinogen: implications for platelet adhesion and spreading. Thromb Haemost. 1998;79:824-831.
45. Schoen FJ, Levy RJ, Nelson AC, Bernhard WF, Nashef A, Hawley M. Onset and progression of experimental bioprosthetic heart valve calcification. Lab Invest. 1985;52:523-532.
46. Tanimura A, McGregor DH, Anderson HC. Matrix vesicles in atherosclerotic calcification. Proc Soc Exp Biol Med. 1983;172:173-177.
47. Srivatsa SS, Harrity PJ, Maercklein PB, Kleppe L, Veinot J, Edwards WD, Johnson CM, Fitzpatick LA. Increased cellular expression of matrix proteins that regulate mineralization is associated with calcification of native human and porcine xenograft bioprosthetic heart valves. J Clin Invest. 1997;99:996-1009.
48. Murry CE, Giachelli CM, Schwartz SM, Vracko R. Macrophages express osteopontin during repair of myocardial necrosis. Am J Pathol. 1994;145: 1450-1462.
49. Ducy P, Desbois C, Boyce B, Pinero G, Story B, Dunstan C, Smith E, Bonadio J, Goldstein S, Gundberg C, Bradley A, Karsenty G. Increase bone formation in osteocalcin-deficient mice. Nature. 1996;382: 448-452.
50. Proudfoot D, Skepper JN, Shanahan CM, Weissberg PL. Calcification of human vascular cells in vitro is correlated with high levels of matrix Gla protein and low levels of osteopontin expression. Arterioscler Thromb Vasc Biol. 1998;18:379-388.
51. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997;386:78-81.
52. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12:1260-1268.
53. Termine JD, Kleinman HK, Whitson SW, Conn KM, McGarvey ML, Martin GR. Osteonectin, a bone-specific protein linking mineral to collagen. Cell. 1981;26:99-105.
54. Romberg RW, Werness PG, Riggs BL, Mann KG. Inhibition of hydroxyapatite crystal growth by bone-specific and other calcium-binding proteins. Biochemistry. 1986;25:1176-1180.
55. Tracy RP, Andrianorivo A, Riggs BL, Mann KG. Comparison of monoclonal and polyclonal antibody-based immunoassays for osteocalcin: a study of sources of variation in assay results. J Bone Miner Res. 1990;5:451-461.
56. Anderson HC. Matrix vesicle calcification: review and update. Bone Miner Res. 1985;3:109-149.
57. ++-binding proiein SPARC (osteonectin) revealed by in situ hybridization. J Cell Biol. 1987;105:473-482.
58. Schor AM, Schor SL. The isolation and culture of endothelial cells and pericytes from the bovine retinal microvasculature: a comparative study with large vessel cells. Microvasc Res. 1986;32:21-38.
59. Schor AM, Allen TD, Canfield AE, Sloan P, Schor SL. Pericytes derived from the retinal microvasculature undergo calcification in vitro. J Cell Sci. 1990;97:449-461.
60. Boström K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest. 1993;91:1800-1809.
61. Levy RJ, Schoen FJ, Levy JT, Nelson AC, Howard SL, Oshry LJ. Biologic determinants of dystrophic calcification and osteocalcin deposition in glutaraldehyde-preserved porcine aortic valve leaflets implanted subcutaneously in rats. Am J Pathol. 1983;113:143-155.
62. Kao VCY, Wissler W. A study of the immunohistochemical localization of serum lipoproteins and other plasma proteins in human atherosclerotic lesions. Exp Mol Pathol. 1965;4:465-479.
63. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 1989;339:303-305.
64. Rath M, Niendorf A, Reblin T, Dietel M, Krebber H-J, Beisiegel U. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis. 1989;9:579-592.
65. Niendorf A, Rath M, Wolf K, Peters S, Arps H, Beisiegel U, Dietel M. Morphological detection and quantification of lipoprotein(a) deposition in atheromatous lesions of human aorta and coronary arteries. Virchows Arch A Pathol Anat. 1990;417:105-111.
66. Loscalzo J. Lipoprotein(a): a unique risk factor for atherothrombotic disease. Arteriosclerosis. 1990;10:672-679.
67. Scanu AM. Lp(a) as a marker for coronary artery disease risk. Clin Cardiol. 1991;14(suppl I):I-35-I-39.
68. Marmur JD, Thiruvikraman SV, Fyfe BS, Guha A, Sharma SK, Ambrose JA, Fallon JT, Nemerson Y, Taubman MB. Identification of active tissue factor in human coronary atheroma. Circulation. 1996;94:1226-1232.
69. Valenzuela R, Shainoff JR, DiBello PM, Anderson JM, Matsueda GR, Kudryk BJ. Immunoelectrophoretic and immunohistochemical characterizations of fibrinogen derivatives in atherosclerotic aortic intimas and vascular prosthesis pseudo-intimas. Am J Pathol. 1992;141: 861-880.
70. Aeschlimann D, Mosher D, Paulsson M. Tissue transglutaminase and factor XIII in cartilage and bone remodeling. Semin Thromb Hemost. 1996;22:437-443.
71. Irving JT. The sudanophil material at sites of calcification. Arch Oral Biol. 1963;8:737-745.
72. Vyavahare N, Hirsch D, Lerner E, Baskin JZ, Schoen FJ, Bianco R, Kruth HS, Zand R, Levy RJ. Prevention of bioprosthethic heart valve calcification by ethanol preincubation: efficacy and mechanisms. Circulation. 1997;95:479-488.
73. Demer LL. Lipid hypothesis of cardiovascular calcification. Circulation. 1997;95:297-298.
74. Schmid K, McSharry WO, Pameijer CH, Binette JP. Chemical and physicochemical studies on the mineral deposits of the human atherosclerotic aorta. Atherosclerosis. 1980;37:199-210.